NCNA Stock Catalyst: NuCana Granted European Patent for New Anti-Cancer Compounds

Aug 28, 2026 · 3:57pm ET

The patent covers new phosphoramidate derivatives.

Max move

+31.0%

High of day $1.90

Sparker timei

3:57pm ET

NCNA · Aug 28, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

NuCana plc, a clinical-stage biopharmaceutical company, announced it has been granted European Patent Number EP3683225. The patent, titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS", protects the company's novel anti-cancer compounds.

The granted patent underscores NuCana's innovative approach to developing new cancer treatments. With 5,714,677 shares in free float, the company continues to advance its pipeline of potential therapies.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time NCNA sparks.

Download Sniper App →

Catch the next NCNA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →